Among the many policy changes contained within the pending legislation to fund Ohio’s government (House Bill 166), is a provision to tie drug prices to an unproven foreign-based pricing index.
A coalition of businesses and organizations, including the OMA, recently wrote state senators asking them to reject the “International Pricing Index” proposal, as included in the House-passed version of HB166. The letter notes that if the proposal is enacted into law, “there are likely to be negative consequences for Ohians who depend on medication,” as well as for the Ohio economy.
More than 75,000 Ohioans are employed at more than 4,000 locations in the bio-science sector, which would be directly affected by the price control plan. 6/6/2019